Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2Thoracic 1Breast 1

Conditions

Small Cell Lung Carcinoma 4Ovarian Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Advanced Solid Tumors 2Solid Tumors 1Sarcoma 1Neuroendocrine Tumors 1Neoplasms 1Neoplasm Metastasis 1Advanced Solid Tumor 1

Interventions

Paclitaxel 96Carboplatin 81Bevacizumab 62Gemcitabine 36liposomal doxorubicin 32pembrolizumab 30Topotecan 26olaparib 23Taxes 23niraparib 17Immunoglobulin G 17Disulfides 17Docetaxel 16Cyclophosphamide 16Cisplatin 14Nivolumab 11rucaparib 10durvalumab 10Doxorubicin 9Albumin-Bound Paclitaxel 8sargramostim 7pazopanib 7fludarabine phosphate 7fludarabine 7avelumab 7Magnetic Resonance Spectroscopy 7Ifosfamide 7epacadostat 6Trabectedin 6Sorafenib 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Ovarian Neoplasms × PM 01183 × Clear all
NCT01831089 2020-04-10

Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors

PharmaMar

Phase 1 Completed
69 enrolled 17 charts
BreastGynecologicThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Small Cell Lung Carcinoma

NCT02421588 2020-04-03

CORAIL

PharmaMar

Phase 3 Completed
442 enrolled 33 charts
Gynecologic

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡